Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)

NCT02636725 is registered in ClinicalTrials.gov with Jonathan Trent, MD, PhD as lead sponsor.

NCT NCT02636725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02636725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)
Lead sponsor
Jonathan Trent, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
April 19, 2016
Completion date
March 3, 2023
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alveolar soft part sarcoma, soft tissue sarcomas